RSS-Feed abonnieren
DOI: 10.1055/s-0044-1779693
Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study
Funding None.Abstract
Background Prior vaccination is often studied for its impact on individuals' post-infection prognosis. Ayurveda, Yoga, Unani, Siddha and Homeopathy (AYUSH) medicines, advised by the Government of India as prophylaxis during the first wave of the coronavirus disease 2019 (COVID-19) pandemic, were consumed by the masses in 2020. A study was therefore undertaken to observe any association between the prior usage of AYUSH prophylactic medicines and post-infection severity as reported by recovered COVID-19 individuals.
Methods This was a retrospective, multi-centre, cohort study conducted in 21 cities of India from 5th August to 30th November 2020. Data from recovered COVID-19 patients, of either sex or any age, captured information about AYUSH prophylactic medicines intake prior to infection, disease severity, symptomatology, duration of complaints, etc. The study participants were grouped into AYUSH intake and non-intake. Primary composite outcome was the disease clinical course. Secondary clinical outcomes were the rate of and time to clinical recovery.
Results Data of 5,023 persons were analysed. Ayurveda or homeopathic prophylactic medicines were consumed by more than half of the study participants: that is, 56.85% (n = 1,556) and 56.81% (n = 1,555) respectively. The overall adjusted protective effect (PE) of AYUSH prophylactic intake against moderate/severe forms of COVID-19 disease was 56.7% (95% confidence interval [CI], 48.7 to 63.50; p < 0.001). Adjusted PE for homeopathy and Siddha was 52.9% (95% CI, 42.30 to 61.50; p < 0.001) and 59.8% (95% CI, 37.80 to 74.10; p < 0.001), respectively. A statistically significant association was found between AYUSH prophylactic medicine intake and clinical recovery more frequently by the 3rd day of illness (χ2 = 9.01; p = 0.002). Time to resolution of symptoms in the AYUSH intake group was on average 0.3 days earlier than in the non-intake group (p = 0.002).
Conclusion AYUSH prophylactics were associated with statistically significant levels of protection against COVID-19 disease severity. Amongst these, previous intake of homeopathy or Siddha medicines was associated with some protection against moderate/severe illness and with a somewhat quicker clinical recovery. Prospective studies with experimental research design are needed to validate the findings of this study.
Study registration Clinical Trials Registry—India (CTRI/2020/08/027000).
Author Statement
A.C. and D.N. conceptualized the study and developed the protocol and the standard operating procedure (SOP) document. S.P., V.S., M.K., V.P., V.P., B.V., H.R., S.B., N.P., T.P., R.B., V.S., M.D., G.R., U.P., P.P.P., S.P.G., A.R.S., K.C.M., P.P., A.M., A.S., R.K., N.P., A.S., G.D.N., R.K.S., R.S., L.K., S.S., S.P., A.K.S., A.K., N.K., C.R., B.S.J.R.K., V.S.P.K.S., A.D.K. S.S., S.K., P.R., S.G., R.C.S., T.L.S, G.R.C.R., S.P, S.S., G.C. and L.D. participated in finalization of the study protocol and data collection. A.K. monitored the study implementation and provided approvals and inputs for SOP development. A.C. was responsible for overall study administration and coordination with the team at the study site for data collection. A.C., D.N. and S.P. analysed the data. A.C. drafted the first version of the manuscript and made changes with relevant suggestions from all the authors. All the authors approved the version submitted for publication.
Publikationsverlauf
Eingereicht: 05. Juli 2023
Angenommen: 24. November 2023
Artikel online veröffentlicht:
07. Mai 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Wang H, Wang Z, Dong Y. et al. Phase-adjusted estimation of the number of Coronavirus Disease 2019 cases in Wuhan, China. Cell Discov 2020; 6: 10
- 2 India COVID-19 Tracker. Accessed October 29, 2020. Available at: https://www.covid19india.org/
- 3 Worldometers COVID-19 Tracker [Internet]. Accessed October 29, 2020. Available at: https://www.worldometers.info/coronavirus/
- 4 Joshi A, Mewani AH, Arora S, Grover A. India's COVID-19 burdens, 2020. Front Public Health 2021; 9: 608810
- 5 Karotia D, Kumar A. A perspective on India's fight against COVID-19. Epidemiol. Int 2020; 5: 22-28
- 6 Pulla P. Covid-19: India imposes lockdown for 21 days and cases rise. BMJ 2020; 368: m1251
- 7 Sahoo H, Mandal C, Mishra S. et al. Burden of COVID-19 pandemic in India: perspectives from health infrastructure. medRχiv preprint. May 27, 2020
- 8 Ministry of Ayush. Advisory for Coronavirus. January 29, 2020 . Accessed October 29, 2020. Available at: https://pib.gov.in/PressReleasePage.aspx?PRID=1600895
- 9 Ministry of Ayush. Ayurveda's immunity boosting measures for self-care during COVID 19 crisis. Ministry of Ayush. Accessed June 11, 2021. Available at: https://www.mohfw.gov.in/pdf/ImmunityBoostingAYUSHAdvisory.pdf
- 10 Ministry of Ayush. Advisory from Ministry of Ayush for meeting the challenge arising out of spread of corona virus in India. March 07, 2020 . Accessed November 21, 2023. Available at: https://pib.gov.in/newsite/PrintRelease.aspx?relid=200005
- 11 Varma A. COVID-19: Kerala Govt Distributes Homeopathy Medicines to 45 Lakh People to Boost Immunity. Republic World. April 29, 2020 . Accessed October 29, 2020. Available at: https://www.republicworld.com/india-news/general-news/covid-19-kerala-govt-distributes-homeopathy-medicines-to-45-lakh-peop.html
- 12 Press Trust of India. Homeopathic drug given to half of Gujarat population since March. Economic Times. August 24, 2020 . Accessed October 19, 2020. Available at https://health.Economictimes.indiatimes.com/news/pharma/homeopathic-drug-given-to-halfof-gujarat-population-since-march/77718653
- 13 Kotecha R. The journey with COVID-19: initiatives by Ministry of AYUSH. J Ayurveda Integr Med 2021; 12: 1-3
- 14 Patwardhan B, Sarwal R. Significance of AYUSH: India's first line of defence against COVID-19. J Ayurveda Integr Med 2021; 12: 227-228
- 15 Srikanth N, Rana R, Singhal R. et al. Mobile app-reported use of traditional medicine for maintenance of health in India during the COVID-19 pandemic: cross-sectional questionnaire study. JMIRx Med 2021; 2: e25703
- 16 Deb S. The curious case of India's success in taming COVID-19. Mint, February 7, 2021 . Accessed on March 20, 2021. Available at: https://www.livemint.com/opinion/columns/the-curious-case-of-india-s-success-in-taming-covid19–11612711676750.html
- 17 Singh N. India has managed COVID-19 well despite large population…We have 15 deaths per million, says Centre. Times Now, July 9, 2020 . Accessed October 29, 2020. Available at: https://www.timesnownews.com/india/article/we-have-15-deaths-permillion-india-has-managed-covid-19-well-despite-large-population-sayscentre/618961
- 18 Prasad R. Several factors could be behind the low case fatality rate in India. The Hindu, July 20, 2020 . Accessed October 29, 2020. Available at: https://www.thehindu.com/scitech/health/coronavirus-several-factors-could-be-behind-the-low-case-fatalityrate-in-india/article32142605.ece
- 19 Ragni P, Marino M, Formisano D. et al. Association between exposure to influenza vaccination and COVID-19 diagnosis and outcomes. Vaccines (Basel) 2020; 8: 675
- 20 Massari M, Spila-Alegiani S, Fabiani M. et al. Association of influenza vaccination and prognosis in patients testing positive to SARS-CoV-2 swab test: a large-scale Italian multi-database cohort study. Vaccines (Basel) 2021; 9: 716
- 21 Daruiche PSJ, Canoas WS, Figueira KAG, Peres GB. Homeopathy for COVID-19 prevention: report of an intervention at a Brazilian service sector company. Homeopathy 2022; 111: 105-112
- 22 Fujino FMSDC, Olandim AACC, Coggan JA. et al. Homeopathic treatment in patients with COVID-19: analysis of clinical evolution and comparison between cases in 2020 and 2021. Homeopathy 2023; 112: 3-11
- 23 Godatwar K P, Deshpande S, Joshi PS. et al. Clinical evaluation of Chyawanprash as a preventive measure during the COVID-19 pandemic: an open-label, multicentric, randomized, comparative, prospective, and interventional community-based clinical study on healthy individuals. J Indian Sys Medicine 2021; 9: 104-113
- 24 Sarwal R, Dhamija RK, Jain K, Basavaraddi IV. Efficacy of pranayama in preventing COVID-19 in exposed healthcare professionals: a quasi-randomized clinical trial. J Ayurveda Integr Med 2023; 14: 100586
- 25 Natarajan S, Anbarasi C, Sathiyarajeswaran P. et al. Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India. Trials 2021; 22: 623
- 26 Nayak D, Nahar K, Bhalerao R. et al. Effectiveness of Arsenicum album 30C in prevention of COVID-19 in individuals residing in containment zones of Delhi—a prospective, community-based, parallel cohort study. Homeopathy 2022; 111: 261-270
- 27 Nayak D, Devarajan K, Pal PP. et al. Efficacy of Arsenicum album 30C in the prevention of COVID-19 in individuals residing in containment areas—a prospective, multicentre, cluster-randomized, parallel arm, community based, open-label study. Complement Med Res. 2022; 30: 375-385
- 28 Press Information Bureau, Government of India. Ministry of Health and Family Welfare. RT-PCR test detects virus even after it becomes inactive and non-infectious: ICMR, explaining new discharge policy. Mumbai, May 19, 2020 . Accessed April 4, 2023. Available at: https://pib.gov.in/PressReleseDetail.aspx?PRID=1625264
- 29 Ministry of Health and Family Welfare. Clinical Management Protocol: COVID-19 (in adults). Accessed October 29, 2022. Available at: https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf
- 30 World Health Organization. WHO R&D Blueprint: Novel Coronavirus COVID-19 Therapeutic Trial Synopsis. WHO,. 2020 . Accessed November 23, 2023. Available at: https://www.who.int/docs/default-source/blue-print/covid-19-therapeutic-trial-synopsis.pdf
- 31 Nalbandian A, Sehgal K, Gupta A. et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601-615
- 32 Indian Council of Medical Research. National guidelines for Ethics Committees reviewing biomedical & health research during COVID-19 pandemic. 1st ed. Indian Council of Medical Research, April 2020 . Accessed June 11, 2021. Available at: https://www.icmr.gov.in/pdf/covid/techdoc/EC_Guidance_COVID19_06052020.pdf
- 33 Chaudhary A, Nayak D, Pandey S. et al. Homeopathic medicine Arsenicum album 30C for COVID-19 in 2020: a retrospective analysis from mass-level data. Altern Ther Health Med 2022; 28: 72-79